Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT04117295
Other study ID # CAR2019-US
Secondary ID
Status Suspended
Phase N/A
First received
Last updated
Start date July 12, 2021
Est. completion date January 2026

Study information

Verified date December 2023
Source Carmat SA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Feasibility study of the Carmat TAH as a treatment for transplant-eligible patients in severe, end-stage heart failure.


Description:

This is a prospective, multi-center, staged feasibility study designed to assess the initial evidence of safety and performance of the Carmat TAH in the treatment of severe, end-stage heart failure. This study will include up to 7 centers in the US. The study population will include up to 10 transplant-eligible patients enrolled and implanted with the Carmat TAH. Data collection will be recorded prior to implantation of the device and for six months following implant, then long term at 9, 12, 18 and 24 months while the patient remains on the device. Adverse events, as defined by INTERMACS, while on device support will be collected throughout the study until study closure and will be adjudicated by an independent Clinical Event Committee. Progress reports of the clinical outcomes will be reviewed by the DSMB after implantation of each patient and every three months thereafter while any patient is supported with the device. A progress report will be sent to FDA for review after three subjects have been implanted and followed for 60 days. The primary objective of the study is survival on an original Carmat device at 180 days post-implant or survival to cardiac transplantation if occurring before 180 days post-implant.


Recruitment information / eligibility

Status Suspended
Enrollment 10
Est. completion date January 2026
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Must be 18 years of age or older at the time of informed consent 2. Anatomic compatibility confirmed using 3D imaging (CT-scan). 3. Inotrope dependent (with documented attempt to wean) or cardiac Index (CI) < 2.2 L/min/m2 if inotropes are contra-indicated (heart failure due to restrictive or constrictive physiology). 4. On Optimal Medical Management as judged by the investigator based on current Heart Failure practice guidelines (ESC/AHA). 5. Eligible for biventricular Mechanical Circulatory Support according to ISHLT guidelines for mechanical circulatory support: 1. Biventricular failure with at least two of the following hemodynamic/ echocardiographic measurements implying right heart failure: RVEF =30%; RVSWI =0.25mmHg*L/m2; TAPSE =14mm; RV-to-LV end-diastolic diameter ratio >0.72; CVP >15 mmHg; CVP-to-PCWP ratio >0.63; Tricuspid insufficiency grade 4; PAPi<2 2. Treatment-refractory recurrent and sustained ventricular tachycardia or ventricular fibrillation in the presence of untreatable arrhythmogenic pathologic substrate. 3. Heart failure due to restrictive or constrictive physiology (e.g., hypertrophic cardiomyopathy, cardiac amyloidosis / senile or other infiltrative heart disease). 6. Patient has signed the informed consent, has full understanding of procedures, and is committed to following study requirements. 7. Eligible for cardiac transplantation Exclusion Criteria: 1. Known intolerance to anticoagulant or antiplatelet therapies or known Heparin Induced Thrombocytopenia. 2. Presence of any non-temporary mechanical circulatory support 3. Presence of temporary mechanical circulatory support such as Impella (all types) or IABP with a duration greater than 21 days 4. Presence of ECMO with a duration greater than 7 days 5. Patient is intubated and unconscious, or intubated and not awake 6. Coagulopathy defined by platelets < 100k/µl or INR = 1.5 not due to anticoagulant therapy. 7. Cerebrovascular accident < 3 months or symptomatic or a known > 80% carotid stenosis. 8. Known abdominal or thoracic aortic aneurysm > 5 cm that has not been treated. 9. Severe end-organ dysfunction as per any of the following criteria: 1. Total bilirubin > 2.5 mg/dl or cirrhosis evidenced by ultrasound, CT-scan and positive biopsy 2. eGFR < 30ml/min/1.73m2 or the need for chronic renal replacement therapy 10. History of severe Chronic Obstructive Pulmonary Disease with FEV1/FVC <0.7, or FEV1<50% predicted or severe restrictive lung disease. 11. Recent blood stream infection (<7 days). 12. Documented amyloid light-chain (AL amyloidosis). 13. Hemodynamically significant peripheral vascular disease with documented ankle- brachial pressure index (ABPI) <0.3. 14. Illness, other than heart disease, that would limit survival to less than 2 years. 15. Irreversible cognitive dysfunction, psychosocial issues or psychiatric disease, likely to impair compliance with the study protocol and TAH management that in the opinion of the investigator could interfere with the ability to manage the therapy (i.e. non-compliance to heart failure therapy, uncontrolled diabetes, mental health issue, etc.). 16. Current or planned pregnancy or breast feeding (woman of childbearing age will have to show negative pregnancy test). 17. Patient is currently enrolled or has participated in the last 30 days in another therapeutic or interventional clinical study that is likely to confound the study results or affect the study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Carmat Total Artificial Heart
Heart replacement therapy

Locations

Country Name City State
United States Baylor University Medical Center Dallas Texas
United States Duke University Medical Center Durham North Carolina
United States University of Louisville Jewish Hospital Louisville Kentucky
United States VCU Medical Center Richmond Virginia

Sponsors (1)

Lead Sponsor Collaborator
Carmat SA

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Survival Proportion of patients surviving on the Carmat TAH 180 days
Secondary Survival without Permanent Neurologic Deficit Proportion of patients surviving post implant without a permanent disabling stroke (Modified Rankin Scale >3) 180 days
Secondary Post transplant survival Proportion of patients surviving 30 days post-transplant 30 days
Secondary Change in functional status New York Heart Association (NYHA) functional classification (regression scale I, II, III, IV) 180 days
Secondary Change in functional status measured by the Six Minutes Walk Test The 6-min walk test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk distance provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise. 180 days
Secondary Generic health status change Measured with the EuroQol EQ-5D questionnaire, a descriptive system of health-related quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses (EQ-5D-5L). The responses record five levels of severity (1:no problems; 2:slight problems; 3:moderate problems 4:severe problems; 5:extreme problems) within a particular EQ-5D dimension.
Measured with the Kansas City Cardiomyopathy Questionnaire, a self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
180 days
Secondary Adverse Events Adverse Event Rates will be captured per the INTERMACS definitions 180 days
Secondary Hospital readmission rate Rate of unplanned readmissions to the hospital 180 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06063811 - Ventricular Tachycardia Ablation in LVAD Patients
Withdrawn NCT04782245 - Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List Phase 2
Active, not recruiting NCT04351945 - Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors
Recruiting NCT03966313 - Perioperative Modification of Hemostasis During Ventricular Assist Device Implantation
Recruiting NCT02592499 - Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure N/A
Active, not recruiting NCT00483197 - VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial Phase 3
Active, not recruiting NCT00490321 - VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy Phase 3
Completed NCT04543747 - Mechanical Circulatory Support Korea Post Market Surveillance Study (PMS)
Recruiting NCT04293575 - Transcatheter Mitral Valve Repair as Bridge Therapy to Heart Transplantation
Recruiting NCT04641416 - Noninvasive Cardiovascular Diagnosis of Patients With Fully Magnetically Levitated Blood Pumps
Completed NCT00490347 - VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility Trial Phase 2
Completed NCT05353816 - Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial N/A
Completed NCT04480151 - ECLS Versus IMPELLA™ as Bridge to LVAD (ECI-BLAD)
Recruiting NCT04205760 - Preoperative Nutritional Optimization and Physical Exercise for Patients Scheduled for Elective Implantation for a Left-Ventricular Assist Device Phase 3
Recruiting NCT06345521 - Etablishment of Follow-up System and End-Stage Heart Registration Platform for Pediatric Heart Failure
Recruiting NCT04768322 - LVAD Versus GDMT in Ambulatory Advanced Heart Failure Patients N/A
Completed NCT02248974 - Development & Testing of a Decision Aid for LVAD Placement N/A
Completed NCT06152562 - Evaluation of Platelet Therapy Response in Left Ventricular Assist Device Patients
Completed NCT05928273 - Corheart 6 LVAS LTFU N/A
Recruiting NCT04951999 - AssocIation of PULSatility and Occurrence of Complications Related to Mechanically Assisted Circulatory Support N/A